Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAF(V600E) Mutated Papillary Thyroid Cancer: Two Case Reports

Background: A multi-institutional, randomized phase II trial of continuous dosing of dabrafenib with or without trametinib is ongoing in metastatic thyroid cancer. Preclinical evidence and emerging clinical experience in other cancers support evaluating intermittent dosing of these two agents to ach...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Thyroid
Hlavní autoři: White, Paul S., Pudusseri, Anita, Lee, Stephanie L., Eton, Omar
Médium: Artigo
Jazyk:Inglês
Vydáno: Mary Ann Liebert, Inc. 2017
Témata:
Case Studies, and Patients with Remarkable Features or Rare Disorders
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6874808/
https://ncbi.nlm.nih.gov/pubmed/28805135
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/thy.2017.0106
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky